PFM Health Sciences, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001442756

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2024 · 76 positions · Total reported value $1.41B · Top-10 concentration 50.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.8% · 24 new · 28 cut · 39 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.9% · vs SPY -7.0% · Prev Value $1.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.3% · vs SPY +0.2% · Latest Value $978.49M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2024 13F filing, PFM Health Sciences, LP disclosed 76 equity positions with a combined reported value of $1.41B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were LLY ($230.55M), IEF ($92.45M), THC ($62.02M). By sector, the heaviest allocations are Health Care 78.5%, Industrials 4.4%. Versus the prior quarter, allocation shifted toward Other (+12.6pp), Technology (+0.6pp) and away from Industrials (-0.9pp), Health Care (-11.9pp).

Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q4 2024 were IEF ($92.45M), NVO ($28.81M), DXCM ($25.57M).

Of the 39 positions fully exited versus the prior quarter, the largest were CYTK ($92.78M), MRK ($61.64M), ACHC ($43.51M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • IEF ISHARES TR · $92.45M
  • NVO NOVO-NORDISK A S · $28.81M
  • DXCM DEXCOM INC · $25.57M
  • NBIX NEUROCRINE BIOSCIENCES INC · $22.77M
  • IJH ISHARES TR · $21.66M
  • RSP INVESCO EXCHANGE TRADED FD T · $18.93M
  • UTHR UNITED THERAPEUTICS CORP DEL · $18.52M
  • CAH CARDINAL HEALTH INC · $17.52M

Fully Exited (vs previous quarter)

  • CYTK CYTOKINETICS INC · prev qtr: $92.78M · history
  • MRK MERCK & CO INC · prev qtr: $61.64M
  • ACHC ACADIA HEALTHCARE COMPANY IN · prev qtr: $43.51M
  • ELV ELEVANCE HEALTH INC FORMERLY · prev qtr: $29.35M
  • AMGN AMGEN INC · prev qtr: $29.09M
  • BDX BECTON DICKINSON & CO · prev qtr: $24.52M
  • INSP INSPIRE MED SYS INC · prev qtr: $20.75M
  • EPIX ESSA PHARMA INC · prev qtr: $16.62M

Insider Transactions (Form 4)

Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-69012 (status: Approved), registered 2008-04-10
  • Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 2 hedge funds
  • Website: pfmhealthsciences.com

Portfolio Structure

  • 96 positions · $1.14B reported value (Q2 2026)
  • Top 10 holdings = 34.6% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
  • Average position size: $11.89M

Sector Tilt

  • Health Care 92.9%
  • Industrials 5.1%
  • Consumer Staples 1.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 32 new, 24 added, 40 reduced, 14 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.5%
Technology 0.8%
Materials 0.2%
Other 16.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 298.64K $230.55M 16.36%
16.36%
Hold
2 1.00M $92.45M 6.56%
6.56%
New
3 491.33K $62.02M 4.40%
4.40%
Reduce
4 331.74K $58.95M 4.18%
4.18%
Reduce
5 97.50K $55.57M 3.94%
3.94%
Hold
6 126.99K $51.14M 3.63%
3.63%
Reduce
7 93.07K $48.58M 3.45%
3.45%
Reduce
8 467.43K $39.55M 2.81%
2.81%
Hold
9 166.26K $39.48M 2.80%
2.80%
Hold
10 63.70K $39.17M 2.78%
2.78%
Reduce
11 525.40K $38.90M 2.76%
2.76%
Add
12 213.98K $38.39M 2.72%
2.72%
Hold
13 57.30K $28.99M 2.06%
2.06%
Reduce
14 125.52K $28.81M 2.04%
2.04%
Hold
15 334.90K $28.81M 2.04%
2.04%
New
16 128.64K $26.98M 1.91%
1.91%
Add
17 328.76K $25.57M 1.81%
1.81%
New
18 166.80K $22.77M 1.62%
1.62%
New
19 111.85K $21.98M 1.56%
1.56%
Hold
20 59.05K $21.91M 1.55%
1.55%
Add
21 347.64K $21.66M 1.54%
1.54%
New
22 83.04K $21.07M 1.50%
1.50%
Reduce
23 69.44K $20.84M 1.48%
1.48%
Reduce
24 70.09K $20.40M 1.45%
1.45%
Hold
25 108.04K $18.93M 1.34%
1.34%
New
26 52.50K $18.52M 1.31%
1.31%
New
27 148.17K $17.52M 1.24%
1.24%
New
28 431.92K $16.13M 1.15%
1.15%
New
29 179.10K $16.13M 1.15%
1.15%
Add
30 307.50K $13.82M 0.98%
0.98%
New
31 54.80K $12.11M 0.86%
0.86%
New
32 32.35K $11.65M 0.83%
0.83%
Reduce
33 55.38K $11.64M 0.83%
0.83%
Add
34 860.82K $11.57M 0.82%
0.82%
Hold
35 83.81K $11.53M 0.82%
0.82%
New
36 4.39M $11.02M 0.78%
0.78%
Reduce
37 21.04K $10.95M 0.78%
0.78%
Reduce
38 119.51K $9.20M 0.65%
0.65%
Reduce
39 144.50K $8.75M 0.62%
0.62%
New
40 397.02K $8.75M 0.62%
0.62%
New
41 7.75M $8.53M 0.60%
0.60%
Hold
42 12.43K $7.28M 0.52%
0.52%
New
43 52.39K $7.21M 0.51%
0.51%
Reduce
44 371.77K $6.23M 0.44%
0.44%
Add
45 3.88M $6.16M 0.44%
0.44%
Reduce
46 150.00K $5.42M 0.39%
0.39%
New
47 180.97K $5.29M 0.38%
0.38%
New
48 283.16K $5.00M 0.35%
0.35%
Add
49 117.00K $4.59M 0.33%
0.33%
Reduce
50 56.60K $4.34M 0.31%
0.31%
Reduce

FAQ

What did PFM Health Sciences, LP buy in 2024-Q4?

In its 2024-Q4 13F filing, PFM Health Sciences, LP reported 76 equity positions worth $1.41B in aggregate; its largest disclosed positions were LLY ($230.55M), IEF ($92.45M), THC ($62.02M).

How large is PFM Health Sciences, LP's portfolio?

PFM Health Sciences, LP reported $1.41B of long equity holdings across 76 positions as of 2024-Q4. Top-10 holdings account for 50.9% of reported value.

What is PFM Health Sciences, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pfm-health-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →